Summary
80 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 47% a year over the last 3 years.
- Out of every 100 USD of revenue, 18 USD is left as net profit.
- It earns 14 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $91.3M against $17.8M.
What to watch
- Revenue fell by 8.7% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 11.1 USD for 1 USD of yearly profit. Over the last five years it was 14.0 USD on average.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it fell by 8.7% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 78 USD
- Sales and administration 6.9 USD
- Taxes and other -2.8 USD
- Net profit 18 USD
Net profit, industry median (Chemicals) 4.7 USD
Out of every 100 USD of revenue, 18 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 3
- Hold 0
- Sell 0
Today's price within the analysts' price targets
The average target of $60 is 48% above today's price. 100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Other Member 100%
By region
The company reports no revenue by region.
Other Member brings in 100% of revenue.
Segments in detail